Opthea Limited

About Opthea Limited

Opthea is dedicated to developing novel therapies to treat vision-threatening eye diseases, particularly wet age-related macular degeneration (wet AMD). Their mission is to deliver superior vision outcomes for healthier and fuller lives by pioneering innovative treatments that elevate the current standard of care.

Products & Services

Sozinibercept:A novel, first-in-class anti-VEGF-C/D 'trap' inhibitor designed for use in combination with standard-of-care anti-VEGF-A therapies to deliver superior visual outcomes for wet AMD patients. It is currently in Phase 3 clinical trials (COAST and ShORe) with topline results expected in early Q2/2025 and mid-2025, respectively.

Specialties

Wet Age-Related Macular Degeneration (Wet AMD) Vision-Threatening Eye Diseases Anti-VEGF-C/D Therapies Clinical Trials for Retinal Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Entitlement Offer T: - FT: Entitlement Offer	A: 36900000 MR: - FA: A$55.9 million FAN: 36900000	D: 2024-07-15 FD: 2024-07-15	1 investors
2	RT: Retail Entitlement Offer T: - FT: Retail Entitlement Offer	A: 36900000 MR: - FA: A$55.0m FAN: 36900000	D: 2024-06-18 FD: 2024-06-18	-
3	RT: Equity Financing (Entitlement Offer and Placement) T: - FT: Equity Financing (Entitlement Offer and Placement)	A: 113200000 MR: - FA: A$171.5 million FAN: 113200000	D: 2024-06-13 FD: 2024-06-13	-
4	RT: Equity Offering T: - FT: Equity Offering	A: 150000000 MR: - FA: up to A$227.3 million FAN: 150000000	D: 2024-06-11 FD: 2024-06-11	-
5	RT: Debt T: - FT: Debt	A: 85000000 MR: - FA: US$85 million FAN: 85000000	D: 2023-12-27 FD: 2023-12-27	3 investors
6	RT: R&D Tax Incentive T: - FT: R&D Tax Incentive	A: 5900000 MR: - FA: A$8.8 million FAN: 5900000	D: 2023-12-19 FD: 2023-12-19	-
7	RT: Equity Financing T: - FT: Equity Financing	A: 57600000 MR: - FA: A$90.0 million FAN: 57600000	D: 2023-08-24 FD: 2023-08-24	-
8	RT: R&D Tax Incentive T: - FT: R&D Tax Incentive	A: 6300000 MR: - FA: A$8.7 million FAN: 6300000	D: 2023-03-07 FD: 2023-03-07	1 investors

Entitlement Offer Latest

2024-07-15

$36.9M

1 investor (Pro only)

Retail Entitlement Offer 2024-06-18

$36.9M

Equity Financing (Entitlement Offer and Placement) 2024-06-13

$113.2M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Karen Adams

Vice President, Finance & Company Secretary

LinkedIn (Pro only)

J

Jeremy M. Levin

Chairman of the Board

LinkedIn (Pro only)

K

Kathy Connell

Non-Executive Director and Chair of Remuneration Committee

LinkedIn (Pro only)

L

Lawrence Gozlan

Chair of Nominations and Governance Committee, Non-Executive Director

View 1 more team members with Pro

Unlock Full Team Directory

Recent News

Opthea Limited Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

About Opthea Limited

Products & Services

Specialties

Funding History

Growth Metrics

Team & Leadership

Recent News

Opthea Limited Announces New Product Launch

Leadership Team Expands with Industry Veteran

Company Recognized as Industry Leader

Key Competitors

Competitor Alpha

Competitor Beta

Competitor Gamma

Competitor Delta

Company Details

Similar Companies

Technology Stack